Hedi Brahim - Transgene CEO Director
| TNG Stock | EUR 0.72 0.01 1.41% |
Insider
Hedi Brahim is CEO Director of Transgene SA
| Age | 42 |
| Phone | 33 3 88 27 91 00 |
| Web | https://www.transgene.fr |
Transgene Management Efficiency
The company has return on total asset (ROA) of (0.1628) % which means that it has lost $0.1628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3623) %, meaning that it generated substantial loss on money invested by shareholders. Transgene's management efficiency ratios could be used to measure how well Transgene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Stefanie Magner | Genfit | 42 | |
| Franois Romagn | Innate Pharma | 59 | |
| Yves MD | AB Science SA | N/A | |
| AnneJuliette MA | Nanobiotix SA | 49 | |
| Earl Bergey | Nanobiotix SA | 68 | |
| Elsa Borghi | Nanobiotix SA | N/A | |
| Jean Fourni | Innate Pharma | N/A | |
| Pascal Caisey | Genfit | 55 | |
| Brandon Owens | Nanobiotix SA | N/A | |
| Marc Bonneville | Innate Pharma | 63 | |
| Alessandro MD | Innate Pharma | N/A | |
| Alexis BERNARD | AB Science SA | N/A | |
| Kathryn McNeil | Nanobiotix SA | 48 | |
| Sarah Gaubert | Nanobiotix SA | N/A | |
| Pr Prasad | Nanobiotix SA | 78 | |
| Bart Rhijn | Nanobiotix SA | N/A | |
| Laurent MBA | AB Science SA | N/A | |
| Laurent Levy | Nanobiotix SA | 50 | |
| Odile Belzunce | Innate Pharma | 43 | |
| Mondher MD | Innate Pharma | 65 | |
| Harshad KULKARNI | AB Science SA | N/A | |
Management Performance
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 |
Transgene SA Leadership Team
Elected by the shareholders, the Transgene's board of directors comprises two types of representatives: Transgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Transgene. The board's role is to monitor Transgene's management team and ensure that shareholders' interests are well served. Transgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Transgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maud MD, VP Officer | ||
| Eric Quemeneur, Ex Officer | ||
| Gaelle Stadtler, VP HR | ||
| JeanPhilippe Del, VP CFO | ||
| Hedi Brahim, CEO Director | ||
| Elisabetta Castelli, Director Relations | ||
| Lucie Larguier, Director IR | ||
| Steven RPh, VP Officer | ||
| LLM JD, Gen VP | ||
| Philippe Slos, Head Laboratory |
Transgene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Transgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 144.73 M | |||
| Shares Outstanding | 100.2 M | |||
| Shares Owned By Institutions | 1.70 % | |||
| Price To Earning | 18.08 X | |||
| Price To Book | 3.39 X | |||
| Price To Sales | 10.07 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Transgene Stock
Transgene financial ratios help investors to determine whether Transgene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.